News for Altimmune, Inc. (ALT)

Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move. David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune. It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway. Click for my ALT stock update.

The stock market experienced a significant rally, bouncing back from recent declines. The S&P 500 surged 2.1%, the Dow Jones Industrial Average rose by 674 poin

Altimmune (NASDAQ:ALT) stock surges on buyout rumors after R&D updates. Read more here.

Altimmune Inc. (ALT) surges 13% on takeover speculation as reports suggest a strategic review with major pharma firms.

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company, today announced that members of

**media[555335]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Feb 27, 2025 / 01:30PM GMTOperator Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call.

Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsLee Roth - President, Burns McClellan,...

**media[552088]**

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational Ne

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascula

**media[545501]**

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT stock is a Buy.

On December 31, 2024, AMERIPRISE FINANCIAL INC (Trades, Portfolio) executed a noteworthy transaction by acquiring 1,378,854 shares of Altimmune Inc (ALT) at a t

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI launches shopping agent Operator; Etsy, eBay tick higher.

Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors.

Move over, Novo Nordisk and Eli Lilly. Why Pfizer and Roche look like top choices for investors.